Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 30 April 2025, 13:17 HKT/SGT
Share:
    

Source: Eisai
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star

TOKYO, Apr 30, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Representative Corporate Officer and CEO Haruo Naito has been selected to receive the Order of the Rising Sun, Gold and Silver Star at the 2025 Spring Conferment of Decorations. The Order of the Rising Sun, Gold and Silver Star is awarded to individuals who have made distinguished contributions to Japan or the Japanese public in various areas of society. The conferral ceremony will take place at the Imperial Palace on May 9, 2025.

As the Representative Corporate Officer and CEO of Eisai, Haruo Naito has been promoting patient-centric management based on the human health care Concept (hhc Concept) for many years. As a result, he has contributed to fulfilling global healthcare needs through the development of innovative new drugs, including Alzheimer's disease and anti-cancer treatments, as well as continued efforts in global health, such as addressing neglected tropical diseases. He has also been recognized for leading discussions on various institutional reforms, including the drug pricing system and R&D tax system, on behalf of industry associations such as the Japan Pharmaceutical Manufacturers Association, contributing to the improvement of public health quality and the healthy development of the industry.

Comment from Haruo Naito on Receiving the Decoration

I am deeply honored to have been awarded the Order of the Rising Sun, Gold and Silver Star. Since assuming the position of Representative Director and President of Eisai Co., Ltd. in 1988, I have established that patients are the main figures in healthcare. By having our employees spend time with the patients to understand their anxieties, and driven by a strong desire to relieve them somehow, we have been promoting the creation of innovations to meet unmet needs, particularly in the dementia and oncology areas.

With a strong belief in delivering these new treatments to patients who need them regardless of the healthcare system or income level of each country, I have worked to improve access to medicines in countries including developing and emerging nations. Through the activities of industry associations, I have also been committed to the development of the pharmaceutical industry, whose mission is to protect the lives and health of the public.

With this honor, I intend to strive even harder to fulfill my mission of increasing satisfaction for patients in Japan and around the world, contributing to health and welfare, and working towards relieving anxiety over health and reducing health disparities.

Biography of Haruo Naito

Born on December 27, 1947
Mar. 1972 - Graduated from Keio University Faculty of Business and Commerce
Jun. 1974 - Received MBA from Northwestern University Kellogg School of Management Oct. 1975 - Joined Eisai
Apr. 1983 - Senior Director, R&D Promotion Department, Eisai Jun. 1983 - Director, Eisai
Apr. 1985 - General Manager, R&D, Eisai Jun. 1985 - Managing Director, Eisai
Jun. 1986 - Representative Director and Senior Managing Director, Eisai Jun. 1987 - Representative Director and Deputy President, Eisai
Apr. 1988 - Representative Director and President, Eisai
Jun. 2003 - Representative Director, President and Chief Executive Officer (CEO), Eisai Jun. 2004 - Director, President (Representative Corporate Officer) and CEO, Eisai
Jan. 2006 - Chair, The Naito Foundation (current)
Jun. 2014 - Director, Representative Corporate Officer and CEO, Eisai (current)

Industry Association History

May 1998 - Vice President, Japan Pharmaceutical Manufacturers Association
May 1998 - Vice President, Federation of Pharmaceutical Manufacturers' Associations of Japan May 1998 - President, Pharmaceutical Manufacturers’ Association of Tokyo
Nov. 2009 - President, International Federation of Pharmaceutical Manufacturers & Associations May 2012 - President, Federation of Pharmaceutical Manufacturers' Associations of Japan
May 2016 - Vice President, Federation of Pharmaceutical Manufacturers' Associations of Japan May 2016 - Chairman, Pharmaceutical Manufacturers’ Association of Tokyo

Major Honors Received

Apr. 1999 - Awarded Honorary Commander of the Order of the British Empire (CBE) by the United Kingdom
Jun. 2014 - Awarded Knight Commander of the Order of the British Empire (KBE) by the United Kingdom

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 12, 2025 12:20 HKT/SGT
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 8, 2025 16:49 HKT/SGT
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sept 4, 2025 09:56 HKT/SGT
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Sept 3, 2025 10:32 HKT/SGT
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sept 1, 2025 12:44 HKT/SGT
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Aug 29, 2025 17:17 HKT/SGT
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 25, 2025 18:30 HKT/SGT
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 18, 2025 08:11 HKT/SGT
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: